Use of psychotropic drugs in patients with epilepsy: interactions and seizure risk

References

• Krishnamoorthy ES. Neuropsychiatric disorders in epilepsy — epidemiology and classification. In: The Neuropsychiatry of Epilepsy Trimble MR, Schmitz B (Eds). Cambridge University Press, Cambridge, UK, 5–17 (2002).
   Google Scholar
• Shorvon SD, Tallis RC, Wallace HK. Antiepileptic drugs: coprescription of proconvulsant drugs and oral contraceptives: a national study of antiepileptic drug prescribing practice. J Neurol Neurosurg. Psychiatry 72(1), 114–115 (2002).
   Google Scholar
• Perucca E. NICE guidance on newer drugs for epilepsy in adults. Br: Med. J 328(7451), 1273–1274 (2004)
   Google Scholar
• Besag FM. Behavioural effects of the newer antiepileptic drugs: an update. Expert Opin. Drug Sal. 3(1), 1–8 (2004).
   Google Scholar
• ••Updated review on the behavioral effectsof antiepileptic drugs.
   Google Scholar
• Ketter TA, Post RM, Theodore WH. Positive and negative psychiatric effects of anti-epileptic drugs in patients with seizure disorders. Neurology53 (5 Suppl. 2), S53—S67 (1999).
   Google Scholar
• ••Interesting review discussing the biologicmechanisms underlying the behavioral effects of antiepileptic drugs and theorizing their possible use as psychoactive medications in patients with epilepsy.
   Google Scholar
• Mula M, Trimble MR, Lhatoo SD, Sander JW. Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia 44(5), 659–663 (2003).
   PubMed Web of Science ®Google Scholar
• Mula M, Trimble MR, Yuen A, Liu RS, Sander RV. Psychiatric adverse events during levetiracetam therapy. Neurology 61(5), 704–706 (2003).
   PubMed Web of Science ®Google Scholar
• Mula M, Trimble MR, Sander RV. The role of hippocampal sclerosis in topiramate-related depression and cognitive deficits in people with epilepsy. Epilepsia 44(12), 1573–1577 (2003).
   PubMed Web of Science ®Google Scholar
• Mula M, Trimble MR. The importance of being seizure free: topiramate and psychopathology in epilepsy. Epilepsy Behav. 4(4), 430–434 (2003).
   Google Scholar
• Dunn RT, Frye MS, Kimbrell TA, Denicoff KD, Leverich GS, Post RM. The efficacy and use of anticonvulsants in mood disorders. Clin. Neuropharmacol. 21(4) 215–235 (1998)
   PubMed Web of Science ®Google Scholar
• Trimble MR. Carbamazepine. Clinical efficacy and use in psychiatric disorders. In: Antiepileptic Drugs. Fifth Edition. Levy RH, Mattson RH, Meldrum BS, Perucca E (Eds). Lippincott Williams 8z Wilkins, PA, USA, 278–284 (2002).
   Google Scholar
• Wang BPW, Ketter TA, Becker OV, Nowakowska C. New anticonvulsant medication uses in bipolar disorder. CNS Spectr. 8(21), 930–947 (2003).
   Google Scholar
• Trimble MR. Oxcarbazepine. Clinical efficacy and use in psychiatric disorders. In: Antiepileptic thugs. Fifth Edition. Levy RH, Mattson RH, Meldrum BS, Perucca E (Eds). Lippincott Williams 8z Wilkins, PA, USA, 476–478 (2002).
   Google Scholar
• Greist JH. Gabapentin. Clinical efficacy and use in psychiatric disorders. In: Anti-epileptic drugs. Fifth Edition. Levy RH, Mattson RH, Meldrum BS, Perucca E (Eds). Lippincott Williams 8z Wilkins, PA, USA, 349–353 (2002).
   Google Scholar
• Hurley SC. Lamotrigine update and its use in mood disorders. Ann. Pharmacother. 36, 860–873 (2002).
   PubMed Web of Science ®Google Scholar
• Pande AC, Feltner DE, Jefferson RV et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin. Psychopharmacol. 24(2), 141–149 (2004).
   Web of Science ®Google Scholar
• Smith D, Baker G, Davies G, Dewey M, Chadwick DW. Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia 34 (2), 312–322 (1993).
   PubMed Web of Science ®Google Scholar
• Gillham R, Kane K, Bryant-Comstock L, Brodie MJ. A double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health-related quality of life as an outcome measure. Seizure 9 (6), 375–379 (2000)
   PubMed Web of Science ®Google Scholar
• Chris Sackellares J, Jacqueline Kwong W, Vuong A, Hammer AE, Barrett PS. Lamotrigine monotherapy improves health-related quality of life in epilepsy: a double-blind comparison with valproate. Epilepsy Behav. 3(4), 376–382 (2002).
   Google Scholar
• Edwards KR, Sackellares JC, Vuong A, Hammer AE, Barrett PS. Lamotrigine monotherapy improves depressive symptoms in epilepsy: a double-blind comparison with valproate. Epilepsy Behav. 2(1), 28–36 (2001).
   PubMed Web of Science ®Google Scholar
• Kalogjera-Sackellares D, Sackellares JC. Improvement in depression associated with partial epilepsy in patients treated with lamotrigine. Epilepsy Behav. 3(6), 510–516 (2002).
   PubMed Web of Science ®Google Scholar
• Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol. 2(8), 473–481 (2003).
   Google Scholar
• ••Second part of a very comprehensive andupdated review on antiepileptic drug interactions. In this paper, the reader can find what is really clinically relevant.
   Google Scholar
• Monaco F, Cicolin A. Interaction between anticonvulsant and psychoactive drugs. Epilepsia 40 (Suppl. 10), 571—S76 (1999).
   Google Scholar
• Mula M, Monaco Antiepileptic—antipsychotic drug interactions. A critical review of the evidence. Clin. Neuropharmacol. 25(5), 280–289 (2002).
   Google Scholar
• Mula M, Trimble MR. Pharmacokinetic interactions between antiepileptic and antidepressant drugs. World J. Biol. Psychiatry 4(1), 21–24 (2003).
   Google Scholar
• Rudorfer MV, Potter WZ. Metabolism of tricyclic antidepressants. Cell. MoL Neurobiol. 19(3), 373–409 (1999).
   PubMed Web of Science ®Google Scholar
• Gram LF, Guentert TW, Grange S, Vistisen K, Brosen K. Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study. Clin. Pharmacol. Ther 57(6), 670–677 (1995).
   Google Scholar
• Daniel W Metabolism of psychotropic drugs: pharmacological and chemical relevance. Pol. J Pharmacol. 47(5), 367–379 (1995).
   PubMedGoogle Scholar
• Nemeroff CB, De Vane CL, Pollock, BG. Newer antidepressants and cytochrome P450 system. Am. J Psychiatry 153, 311–320 (1996).
   Google Scholar
• Pollock BG. Recent development in drug metabolism of relevance to psychiatrists. Harvard Rev Psychiatry2,204–213 (1994).
   PubMed Web of Science ®Google Scholar
• Brosen K, Skjelbo E, Rasmussen BB, Paulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem. Pharmacol. 45,1211-1214 (1993).
   Google Scholar
• Ereshefsky L, Dugan D. Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine. Depress. Anxiety 12 (Suppl. 1), 30–44 (2000).
   Google Scholar
• Spina E, Scordo MG, D'Arrigo C. Metabolic drug interactions with new psychotropic agents. Fundam. Clin. Pharmacol. 17(5), 517–538 (2003)
   Google Scholar
• Otani K, Aoshima T. Pharmacogenetics of classical and new antipsychotic drugs. Ther. Drug Monit. 22(1), 118–121 (2000).
   PubMed Web of Science ®Google Scholar
• Daniel WA, Syrek M, Rylko Z, Kot M. Effects of phenothiazine neuroleptics on the rate of caffeine demethylation and hydroxylation in the rat liver. Pol. J. Pharmacol. 53(6), 615–621 (2001).
   Google Scholar
• Kudo S, Ishizaki T. Pharmacokinetics of haloperidol: an update. Clin. Pharmacokinet. 37(6), 435–456 (1999).
   PubMed Web of Science ®Google Scholar
• Prior TI, Chue PS, Tibbo P, Baker GB. Drug metabolism and atypical antipsychotics. Eur. Neuropsychopharmacol. 9(4), 301–309 (1999).
   PubMed Web of Science ®Google Scholar
• Fang J, Bourin M, Baker GB. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch. Pharmacol. 359(2), 147–151 (1999).
   Google Scholar
• Ring BJ, Catlow J, Lindsay TJ et al. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. Pharmacol. Exp. Ther 276(2), 658–666 (1996).
   Google Scholar
• Ereshefsky L. Pharmacokinetics and drug interactions: update for new antipsychotics. Clin. Psychiatry57\(Suppl. 11), 12–25 (1996).
   Google Scholar
• Wong SL, Cavanaugh J, Shi H, Awni WM, Granneman GR. Effects of divalproex sodium on amitriptyline and nortriptyline pharmacokinetics. Clin. Pharmacol. Ther. 60,48–53 (1996).
   Google Scholar
• Szymura-Oleksiak J, Wyska E, Wasieczko A. pharmacokinetic interaction between imipramine and carbamazepine in patients with major depression. Psychopharmacology (Berl} 154,38–42 (2001).
   Google Scholar
• Grimsley SR, Jann MW, Carter JG, D'Maello AP, D'Souza MJ. Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clin. Pharmacol. Ther. 50,10–15 (1991).
   Google Scholar
• Spina E, Avenoso A, Pollicino AM, Caputi AP, Fazio A, Pisani F Carbamazepine coadministration with fluoxetine or fluvoxamine. Ther. Drug Monit. 15, 247–250 (1993).
   PubMed Web of Science ®Google Scholar
• Nelson MH, Birnbaum AK, Remmel RP. Inhibition of phenytoin hydroxylation in human liver microsomes by several selective serotonin reuptake inhibitors. Epilepsy Res. 44,71–82 (2001).
   Google Scholar
• Andersen BB, Mikkelsen M, Vesterager A et al. No influence of the antidepressant paroxetine on carbamazepine, valproate and phenytoin. Epilepsy Res. 10,201–204 (1991).
   PubMed Web of Science ®Google Scholar
• Leinonen E, Lepola U, Koponen H. Substituting carbamazepine with oxcarbazepine increases citalopram levels. A report on two cases. Pharmacopsychiatry29, 156–158 (1996).
   Google Scholar
• Rapeport WG, Muirhead DC, Williams SA, Cross M, Wesnes K. Absence of effect of sertraline on the pharmacokinetics and pharmacodynamics of phenytoin. j Clin. Psychiatry 57 (Suppl. 1), 24–28 (1996).
   Google Scholar
• Rapeport WG, Williams SA, Muirhead DC, Dewland PM, Tanner T, Wesnes K. Absence of sertraline-mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine. j Clin. Psychiatry 57\(Suppl. 1), 20–23 (1996).
   Google Scholar
• Bonate PL, Kroboth PD, Smith RB, Suarez E, Oo C. Clonazepam and sertraline: absence of drug interaction in a multiple-dose study. J Clin. PsychopharmacoL 20, 19–27 (2000).
   Google Scholar
• Toy SM, Lucki I, Peirgies AA, Parker VD, Klockowski PM, Chiang ST. Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and diazepam. J. Clin. PharmacoL 35,410–419 (1995).
   PubMed Web of Science ®Google Scholar
• Laroudie C, Salazar DE, Casson JP et al. Carbamazepine-nefazodone interaction in healthy subjects. J Clin. PsychopharmacoL 20,46–53 (2000).
   PubMed Web of Science ®Google Scholar
• Ketter TA, Post RM, Parekh PI, Worthington K. Addition of monoamine oxidase inhibitors to carbamazepine: preliminary evidence of safety and antidepressant efficacy in treatment-resistant depression. J. Clin. Psychiatry 56, 471–475 (1995).
   PubMed Web of Science ®Google Scholar
• Popli AP, Tanquary J, Lamparella V, Masand PS. Bupropion and anticonvulsant drug interactions. Ann. Clin. Psychiatry 7, 99–101 (1995)
   PubMedGoogle Scholar
• Tekle A, al-Kamis KI. Phenytoin—bupropion interaction: effect on plasma phenytoin concentration in the rat. Pharm. PharmacoL 42,799–801 (1990).
   Google Scholar
• Odishaw J, Chen C. Effects of steady-state bupropion on the pharmacokinetics of lamotrigine in healthy subjects. Pharmacotherapy20, 1448–1453 (2000).
   PubMed Web of Science ®Google Scholar
• Guengerich FP. Role of cytochrome P450 enzymes in drug—drug interactions. Adv. PharmacoL 43,7–35 (1997).
   Google Scholar
• Kidron R, Averbuch I, Klein E, Belmaker RH. Carbamazepine-induced reduction of blood levels of haloperidol in chronic schizophrenia. Biol. Psychiatry 20 (2), 219–222 (1985).
   PubMed Web of Science ®Google Scholar
• Jann MW, Ereshefsky L, Saklad SR et al. Effects of carbamazepine on plasma haloperidol levels. J. Clin. Psychopharmacol. 5(2), 106–109 (1985).
   Google Scholar
• Iwahashi K, Miyatake R, Suwaki H, Hosokawa K, Ichikawa Y. The drug—drug interaction effects of haloperidol on plasma carbamazepine levels. Clin. NeuropharmacoL 18,233–236 (1995).
   Google Scholar
• Hirokane G, Someya T, Takahashi S, Morita S, Shimoda K. Interindividual variation of plasma haloperidol concentrations and the impact of concomitant medications: the analysis of therapeutic drug monitoring data. Ther. Drug Monit. 21,82-86 (1999).
   Google Scholar
• Hesslinger B, Normann C, Langosch JM, Klose P, Berger M, Walden J. Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients. J. Clin. PsychopharmacoL 19, 310–315 (1999).
   PubMed Web of Science ®Google Scholar
• Doose DR, Kohl KA, Desai-Krieger D, Natarajan J, Van Kammen DP. No clinically significant effect of topiramate on haloperidol plasma concentration. Eur. NeuropsychopharmacoL 9, S357 (1999).
   Google Scholar
• Spina E, Avenoso A, Facciolà G et al. Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate. Ther. Drug Monit. 22,481-485 (2000).
   Google Scholar
• Ono S, Mihara K, Suzuki A et al. Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes. Psychopharmacology162,50–54 (2002).
   PubMed Web of Science ®Google Scholar
• Mula M, Monaco E Carbamazepine—risperidone interactions in patients with epilepsy. Clin. NeuropharmacoL 25,97–100 (2002).
   PubMed Web of Science ®Google Scholar
• Furukory NY, Hidestrand M, Spina E, Facciola G, Scordo MG, Tybring G. Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP 3A4 enzymes. Drug Metab. Dispos. 29,1263-1268 (2001).
   Google Scholar
• Miceli JJ, Anziano RJ, Robarge L, Mansen RA, Laurent A. The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers. Br. J Clin. PharmacoL 49\(Suppl. 1), S65—S70 (2000).
   Google Scholar
• Facciola G, Avenoso A, Spina E, Perucca E. Inducing effect of phenobarbital on clozapine metabolism in patients with chronic schizophrenia. Ther. Drug Monit. 20,628–630 (1998).
   PubMed Web of Science ®Google Scholar
• Prior TI, Chue PS, Tibbo P, Baker GB. Drug metabolism and atypical antipsychotics. Eur. NeuropsychopharmacoL 9,301–309 (1999).
   PubMed Web of Science ®Google Scholar
• Centorrino F, Baldessarini RJ, Kando J et aL Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate. Am. J. Psychiatry151,123–125 (1994).
   PubMed Web of Science ®Google Scholar
• Facciola G, Avenoso A, Scordo MG et al. Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders. Ther. Drug Monit. 21, 341–345 (1999).
   PubMed Web of Science ®Google Scholar
• Chong SA, Remington G. Ethnicity and clozapine metabolism. Br. J. Psychiatry172, 97 (1998).
   PubMed Web of Science ®Google Scholar
• Lucas RA, Gilfillan DJ, Bergstrom RE A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism. Eur. Clin. PharmacoL 54,639–643 (1998).
   Web of Science ®Google Scholar
• Wong YW, Yeh C, Thyrum PT. The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine. I Clin. PsychopharmacoL 21, 89–93 (2001).
   Google Scholar
• Spina E, Perucca E. Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. Epilepsia. 43\(Suppl. 2), 37–44 (2002).
   Google Scholar
• Furukori H, Otani K, Yasui N et al. Effect of carbamazepine on the single oral dose pharmacokinetics of alprazolam. Neuropsychopharmacology18,364–369 (1998).
   PubMed Web of Science ®Google Scholar
• Backman TJ, Olkkola KT, Ojala M, Laaksovirta H, Neuvonen PS. Concentrations and effects of oral midazolam are greatly reduced in patients on carbamazepine or phenytoin. Epilepsia 37,253–257 (1996).
   Google Scholar
• Torta R, Monaco E Atypical antipsychotics and serotoninergic antidepressants in patients with epilepsy: pharmacodynamic considerations. Epilepsia 43\(Suppl. 2), 8–13 (2002).
   Google Scholar
• Pisani F, Oteri G, Costa C, Di Raimondo G, Di Perri R. Effects of psychotropic drugs on seizure threshold. Drug Sal. 25(2), 91–110 (2002).
   PubMed Web of Science ®Google Scholar
• Hensiek A, Trimble MR. Relevance of new psychotropic drugs for the neurologist. Neurol. Neurosurg. Psychiatry 72,281–285 (2002).
   PubMed Web of Science ®Google Scholar
• Yan QS, Jobe PC, Dailey JW. Evidence that a serotonergic mechanism is involved in the anticonvulsant effect of fluoxetine in genetically epilepsy-prone rats. Eur. Pharmacol. 252,105–112 (1994).
   Google Scholar
• Leander JD. Fluoxetine, a selective serotonin-uptake inhibitor, enhances the anticonvulsant effects of phenytoin, carbamazepine and ameltolide (LY-201116). Epilepsia 33,573–576 (1992).
   PubMed Web of Science ®Google Scholar
• Alldredge BK. Seizure risk associated with psychotropic drugs: clinical and pharmacokinetic considerations. Neurology 53(5 Suppl. 2), S68—S75 (1999).
   Google Scholar
• Devinsky 0, Honigfeld G, Patin J. Clozapine-related seizures. Neurology41 (3), 369–371 (1991).
   Google Scholar
• Pacia SV, Devinsky 0. Clozapine seizures: experience with 5629 patients. Neurology 44,2247–2249 (1994).
   Google Scholar
• Langosch JM, Trimble MR. Epilepsy, psychosis and clozapine. Human Fkithopharmacol. Clin. Exp. 17,115–119 (2002).
   PubMed Web of Science ®Google Scholar
• Kramlinger KG, Post RM. Addition of lithium carbonate to carbamazepine: haematological and thyroid effects. Am. Psychiatry 147,615–620 (1990).
   PubMed Web of Science ®Google Scholar
• Vieweg V, Shutty M, Hundley P, Leadbetter R. Combined treatment with lithium and carbamazepine. Am. J Psychiatry148, 398–399 (1991).
   PubMed Web of Science ®Google Scholar
• Freeman MP, Stool AL. Mood stabilizer combinations: a review of safety and efficacy. Arn. J Psychiatry 155 (1), 12–21 (1998).
   PubMed Web of Science ®Google Scholar
• Chen C, Veronese L, Yin Y. The effects of lamotrigine on the pharmacokinetics of lithium. Br. I Clin. Pharmacol. 50, 193–195 (2000).
   Google Scholar